About 4599

Founded: 2006
Employees: 45
CEO: Masatsune Okajima
WebsiteView website: stemrim.com

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.

Recent 4599 News & Updates

Announcement • Jul 22

Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders

StemRIM Inc. announced that a patent will soon be registered in Mexico for the application related to the novel treatment of cartilage disorders (including traumatic cartilage defect, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the “Regeneration-Inducing Medicine™” development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention: Therapeutic agent for cartilage disorder Region: Mexico Application No.: MX/a/2021/004758 Registration No.: To be determined Applicant: StemRIM, The University of Osaka This patent is intended to expand the indications for Redasemtide, which is currently under development, and the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (including traumatic cartilage defect, osteoarthritis, and osteochondritis dissecans) in Mexico. Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited self-repair capacity, such disorders tend to become chronic and progressive. It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow–derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice. The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant.

Recent updates

No updates

StemRIM Stock Price

4599 Share Price Performance

4599 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

StemRIM Key Details

About 4599

Recent 4599 News & Updates

StemRIM to Report Fiscal Year 2026 Results on Sep 09, 2026

Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders

We're Not Very Worried About StemRIM's (TSE:4599) Cash Burn Rate

Recent updates

StemRIM Competitors

Chugai Pharmaceutical

Takeda Pharmaceutical

Otsuka Holdings

Daiichi Sankyo Company